Raymond James Financial
AEMD icon

Raymond James Financial’s Aethlon Medical AEMD Stock Holding History

Raymond James Financial’s Portfolio AEMD Stock Details AEMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6
Closed -$340 – 4979
2025
Q2 		$340 Buy
+6
New +$805 ﹤0.01% 6722

Other funds holding AEMD

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Raymond James Financial's AEMD Position: Q3 2025 in Review

Raymond James Financial sold out of Aethlon Medical (AEMD) in Q3 2025, closing a stake of 6 shares — an estimated $340 sold.

Raymond James Financial first reported a position in AEMD in Q2 2025 and held it in 1 quarter. The position peaked at $340 in Q2 2025. 14 funds tracked by Wall St. Rank hold AEMD as of Q3 2025.

  • Raymond James Financial reported no remaining Aethlon Medical position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 6 Aethlon Medical shares in Q3 2025, an estimated $340.
  • Raymond James Financial first reported a position in Aethlon Medical in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Aethlon Medical position peaked at $340 in Q2 2025.
  • 14 funds tracked by Wall St. Rank held Aethlon Medical as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.